Advanced Biomed (NASDAQ:ADVB) Stock Price Down 14.4% – Time to Sell?

Posted by Francis Steltz on Aug 9th, 2026

Advanced Biomed Inc. (NASDAQ:ADVB – Get Free Report)’s share price traded down 14.4% during trading on Friday . The stock traded as low as $6.37 and last traded at $6.37. 59,258 shares traded hands during trading, a decline of 99% from the average daily volume of 5,269,758 shares. The stock had previously closed at $7.44.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Read Our Latest Stock Analysis on Advanced Biomed

Advanced Biomed Stock Performance

The stock has a market cap of $10.52 million, a P/E ratio of 1.32 and a beta of -0.39. The stock’s 50-day simple moving average is $6.43.

Advanced Biomed (NASDAQ:ADVB – Get Free Report) last announced its earnings results on Saturday, May 16th. The company reported ($0.38) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Advanced Biomed stock. BlackRock Inc. bought a new position in Advanced Biomed Inc. (NASDAQ:ADVB – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 59,944 shares of the company’s stock, valued at approximately $186,000. BlackRock Inc. owned approximately 3.63% of Advanced Biomed as of its most recent filing with the Securities & Exchange Commission.

Advanced Biomed Company Profile

(Get Free Report)

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.